Sygnomics’ Post

Do Accelerator Programmes for Science Companies Work? Yes - Here's How: Last year, our Neurotech Accelerator, in partnership with Innovate UK, awarded Feasibility Grants - worth a collective £3m - to seven early-stage companies: ➡️MindSpire ➡️MintNeuro ➡️NEUROBITE ➡️NeuroVirt Limited ➡️Samphire Neuroscience ➡️ ESP Diagnostics Limited 🔍For the entire programme, over 30 companies received the award, funded by Innovate UK Biomedical Catalyst, to assess the technical and commercial viability of their projects: 🔨By learning customer discovery and entrepreneurial skills, testing key assumptions and developing your product through workshops and 1-1 coaching, you'll have the tools to gain investment, adapt to the market and scale up. This year, our theme is 𝐀𝐈 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡. With the same expert commercial support and access to grant funding, your AI-driven solutions can reach healthcare markets. Accelerate your journey to commercialisation here: 👉 https://loom.ly/z4VVxsU

Investing for impact in braintech. 🧠 by August Solliv, Author of Impact Supporters. 👇 Why it matters.👇 Braintech is emerging as a crucial impact area due to an aging population and a surge in chronic and neurological diseases. Anne-Sophie Saint-Martin of Newfund highlights that braintech startups in Europe rival those in the USA in quality but face monetization challenges. FDA approval remains a significant hurdle, yet partnerships, like Newfund’s with FondaMental Foundation, help mitigate these risks. The largest trend in braintech is techbio, which accelerates drug discovery and patient care. Understanding these dynamics can guide VCs and LPs in supporting impactful braintech ventures, driving advancements in diagnosing and treating neurological diseases. Read the interview with Anne-Sophie Saint-Martin from Newfund on EUVC Insights! 🔽 https://buff.ly/3XPYaGE #venturecapital #startupfunding #Europe #EUVCInsights

📣We are thrilled to announce that neuroClues is one of the 10 finalists in the Health Tech Challengers, under the Disruptive Diagnosis track! 🌐 Health Tech Challengers is a prestigious platform for digital health startups, giving them the opportunity to showcase how they are shaping the future of healthcare. Out of 10 finalists in each of the 8 digital health tracks, one winner will be chosen based on their pitch, and we are honored to stand alongside such innovative companies. 💥 How is neuroClues disruptive?  Eye movements are the window into the brain. Long before clinical symptoms appear, eye movements can offer clues about neurological health. By providing an objective, quantifiable, and quick way to measure ocular biomarkers, neuroClues could empower clinicians to make more accurate diagnoses—potentially reducing the need for costly and time-consuming tests. 🎯 In essence, we aim to be the stethoscope for the brain. 🙌 A big thank you to Health Tech Challengers and the panel of experts for this recognition. Congratulations to all the other finalists—we’re excited to hear your pitches and learn how your innovations are transforming healthcare! 🚀 And of course, Antoine Pouppez, we can't wait to see you pitch at Health Tech Forward in December, you've got this! #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.

Best wishes to the student teams competing in the PitchRx finals, happening live at 4pm EDT today at Mayo Clinic in Jacksonville, Florida. Dr. Charles Bruce, our medical director, will kick off the event. It's not too late to join us virtually and support teams from Carnegie Mellon University, Georgia Institute of Technology, Harvard Business School, University of California, Santa Cruz, University of Chicago and Vanderbilt University. Register here: https://lnkd.in/gpZBiv-T Both in-person and virtual attendees can vote for the People's Choice Award for the following teams: -UTI-GUARD: Monitoring incontinence in elderly women to alert nurses and prevent UTIs. -OZ-Link Technologies: Enabling programmable delivery of protein therapeutics. -TremTech: Redefining Parkinson’s management through wearable technology for personalized tremor relief. -Theta Neurotech: Wearable EEG patch alerting people with epilepsy of their impending seizures. -Nalopack: Crossbody bag that provides rapid access to naloxone, empowering wearers to save lives while challenging stigma through its design. -Lilypad Health: An at-home non-invasive menstrual blood screening tool for gynecological diseases like high-risk HPV, HIV, and other STDs. -AVOVA Health: Platform that aggregates and explains your blood work history to provide a comprehensive view of your health. -Turmerik: Machine learning platform to match diverse patients to the right clinical trials. -Breezy: AI platform that automates comprehensive patient assessments.

The second baby vc Master Series is here, and this time, we focus on 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬. Register below!🧬 I've been in the VC/startup ecosystem for just under a year now, and I've had the opportunity to work on incredible investments in the healthcare sector❤️. It's been fascinating to explore the plethora of solutions emerging daily, from digital health solutions optimising hospital workflows to advancements in cancer therapeutics and drug discovery platforms. This passion for healthcare allowed me to really connect with fellow members of the baby vc family, including Ghita, Mariam and Zeno. To share this passion further with the rest of the baby vc community and beyond, we're thrilled to announce the launch of this second Master Series focusing on Healthcare and Life Sciences! 🏥 The Health and Life Sciences ecosystem is vast, encompassing various innovations in broad verticals from #DigitalHealth 🩺 to #Medtech💉, #Therapeutics💊, or #Techbio🧪. In this series, you'll have the opportunity to navigate the healthtech ecosystem and explore the nuances between these closely related yet distinct verticals. 💡 To provide a 360-view of the industry's future, each session will feature 𝐤𝐞𝐲 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐥𝐢𝐟𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 across Europe alongside successful startups from the ecosystem.  🚀For the first time, the Masterclass will be 𝐨𝐩𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐞𝐱𝐭𝐞𝐫𝐧𝐚𝐥 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲. Practicalities: 🕝 4 masterclasses - starting on June 5th, 2024 ⌛️Wednesdays from 7:00 pm to 8:30 pm CET 💻 Fully-online format 🧑🤝🧑 Open to Current Fellows, Alumni and Externals 𝐅𝐢𝐥𝐥 𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐦 𝐛𝐞𝐥𝐨𝐰 and I look forward to seeing many of you at the sessions!

In this week's edition, we are excited to share insights from our first-ever study conducted with students through our Student Ambassador program, alongside the latest updates and trends in women's health. Top Highlights : ⭐Novocuff, Inc., a Mountain View, CA-based medical device company, raised $26M in Series A funding led by AXA IM Alts. ⭐Briefly Bio a London, UK-based techbio startup, secured $1.2M led by Compound VC for lab work reproducibility tools. ⭐Huma, a London, UK-based healthcare AI firm, raised over $80M in Series D funding with AstraZeneca among backers. ⭐Bionic, a UK-based personalized supplements provider, secured $15M in Series B funding led by HV Capital. ⭐CatalYm GmbH, a Munich, Germany-based immune therapy firm, raised $150M in Series D led by Canaan Partners and Bioqube Ventures. ⭐Ultrahuman launches App Store ‘PowerPlugs’ Featuring World’s First AFib Detection Technology on a Smart Ring. ⭐ Thrive Global and OpenAI Startup Fund launch Thrive AI Health, aiming to democratize health coaching with an AI focus on chronic disease prevention. Stay informed with our latest insights! Subscribe to our newsletter for more updates and the latest news. https://lnkd.in/gQcW9iug Lupin Eli Lilly and Company European Society of Human Reproduction and Embryology (ESHRE) #femtechindia

Federated learning adoptions and applications in a accelerated speed in many industrial sectors, not just healthcare. We are very pleased to see NVFlare is the choice of many companies, from startup companies to major names in various sectors. Check out NVFlare upcoming release with many exciting features

🌟 Another Ventures&Wine is on its way 🎉 This time, we are diving into AI tools for drug discovery and diagnostics - a brief history from origin to application. Join us for an exhilarating event where we dive deep into the groundbreaking world of Artificial Intelligence and its transformative role in drug discovery, cancer diagnostics, and more. 🧬 What to Expect: Our expert speaker, Michael Green, the CEO of Desupervised and an authority in AI applications, will take us on a captivating journey through the origins and evolution of AI technology. Discover how these innovations are reshaping the landscape of life sciences, accelerating drug development, and revolutionising cancer diagnostics. 🎤 Key Highlights: - The fascinating history of AI and its application in healthcare - Case studies showcasing successful AI applications in drug discovery - Q&A session: Get your burning questions answered! 📅 Date: 10th October 🕒 Time:17:00   📍 Location: Symbion, Fruebjergvej 3, 2100 København Ø Don’t miss this opportunity to gain invaluable insights that could shape the future of medicine! Connect with industry leaders, expand your network, and be part of the conversation that’s driving innovation. 🔗 Register Now: https://lnkd.in/dXBCN8PA Curious to hear more about us? Let's check this 🔍 https://www.rebbls.dk/ Venture&Wine is organised by REBBLS and CPHLabs and supported by Industriens Fond, Københavns Universitet - University of Copenhagen, Symbion Community, HØIBERG - European Patent Attorneys, and VinFraLoire #REBBLSteam #entrepreneurship #AI #LifeSciences #DrugDiscovery #CancerDiagnostics #Innovation #HealthCareTechnology #Networking

🎉 Exciting News Alert! 🚀 Thrilled to announce that one of the exceptional companies in our current cohort, DoMore Diagnostics, has secured a significant milestone on its journey to revolutionize #cancer treatment! 🌟 DoMore Diagnostics, a pioneer in #AI and #deeplearning precision diagnostics for #digitalpathology, has been awarded up to €10 million in grant and equity financing by the prestigious European Innovation Council (EIC) Accelerator program! 🏆 This funding will propel the company through key milestones, leading to the commercial launch and scale-up of its groundbreaking digital biomarker. This milestone not only underscores DoMore Diagnostics' commitment to personalized cancer treatment but also signifies a breakthrough in ensuring better outcomes for patients worldwide. 💪 DoMore Diagnostics' lead product, Histotype Px® Colorectal, marks a paradigm shift in #cancercare. This CE-IVDD marked outcome prediction marker provides invaluable insights for clinicians, guiding personalized treatment decisions for stage II and III #colorectaladenocarcinoma patients. 💡 With the support of the EIC Accelerator program, DoMore Diagnostics is poised to make significant strides towards its mission of personalizing #cancertreatments, driving #innovation in healthcare, and ultimately improving outcomes for patients globally. 🌐 If you are a #healthtech startup aspiring to follow DoMore Diagnostics's success, check out our program here: https://lnkd.in/dz9nT_JB 🥳 #DoMoreDiagnostics #PrecisionMedicine #CancerTreatment #colorectaladenocarcinoma #EICAccelerator #HealthcareInnovation #CDLBerlin #buildsomethingmassive #Congratulations 🎉Torbjørn Furuseth Andreas Berg Storsve Sepp De Raedt

Advice from those who've been there and done it is always helpful. Starting or scaling a business in Life Science or Tech? Have a look/listen.